CROI 16 (Retrovirus) 2009

16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

Intensive smoking cessation programme reports limited success at 6 months

HDL particle concentration predicts cardiovascular disease in SMART

No effect of hormonal contraception on HIV disease progression in large multi-country cohort

Pregnancy, family planning, and HIV acquisition in HPTN 039

Progression and regression of pre-malignant cervical lesions in HIV-positive women from Soweto

CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

HIV testing of infants at immunisation clinics in Kwazulu-Natal

Rapid HIV disease progression in South African infants co-infected with cytomegalovirus (CMV)

Pharmacokinetic studies in very young infants

Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

PI-based ART in children with HIV and HIV/TB coinfection in South Africa

Etravirine dose selection in children aged 6 to 17

Preliminary results from first paediatric raltegravir study

16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

HIV infection in the brain: a long-term limitation of HAART?

When to start HAART – a key research question with the least available data

Major studies rule out any benefit of Interleukin-2 (IL-2): results from ESPRIT and SILCAAT

Higher rates of non-AIDS cancers in HIV positive people

Effect of breast feeding vs formula feeding on maternal health


Premature delivery and mother-to-child HIV transmission: a risk/benefit analysis among women receiving HAART

Risk factors for adverse pregnancy outcomes in Botswana

Higher risk of transmission with delayed control of maternal viral load despite viral loads of <500 copies/mL at delivery

Lopinavir/r containing regimen superior to nevirapine containing regimen in women previously exposed to single dose nevirapine

Covering the nevirapine tail

Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes

High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana

Children on HAART do extremely well at South African clinic

New boosting alternatives to ritonavir: GS-99350 and SPI-452

Interactions with raltegravir: with twice-daily atazanavir and standard dose lamotrigine

Effect of tenofovir on abacavir phosphorylation

Nevirapine: fluconazole and TB treatment

PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy

Identification of drug interactions in clinical practice

Effect of substance abuse on ART pharmacokinetics